Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended July 31, 1997 (Fiscal Year 1997)
Business Overview: The Company develops, manufactures, and markets healthcare products, including contact lenses (CooperVision, Inc.) and surgical instruments (CooperSurgical, Inc.). It also provides healthcare services through psychiatric facilities (Hospital Group of America, Inc.).
Key Financial Metrics
| Metric | Nine Months Ended July 31, 1997 | Nine Months Ended July 31, 1996 |
|---|---|---|
| Net Operating Revenue | $100,988,000 | $77,895,000 |
| Net Income | $15,869,000 | $8,130,000 |
| Earnings Per Share (EPS) | $1.28 | $0.69 |
| Operating Cash Flow | $2,918,000 | $(2,094,000) |
| Cash and Equivalents (End of Period) | $43,291,000 | $3,143,000 |
| Total Debt (Current + Long-term) | $43,248,000 | $48,764,000 |
| Stockholders' Equity | $95,697,000 | $15,330,000 |
Margins: Gross margin on products was 69% for the nine months ended July 31, 1997, compared to 70% in the prior year. Operating margin improved significantly due to revenue growth and cost controls.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 30% year-over-year. Product sales rose 32% driven by CooperVision (CVI) and CooperSurgical (CSI) acquisitions and organic growth. Service revenue from Hospital Group of America (HGA) increased 26% due to higher admissions and outpatient visits.
- Profitability: Net income nearly doubled, increasing from $8.1 million to $15.9 million. This was aided by a $2.1 million reduction in the deferred tax asset valuation allowance.
- Liquidity Transformation: The Company shifted from a net debt position of $41.9 million at the prior fiscal year-end to a net cash position of $2.9 million. This was primarily driven by a $50.5 million follow-on stock offering used to repay debt.
- Debt Reduction: Total debt decreased. The Company repaid approximately $22 million of debt since the offering and called for the redemption of $21.9 million in Senior Subordinated Secured Notes due September 1, 1997.
Guidance, Outlook, and Risks
Management Commentary: Management believes the Company is well-positioned for acquisitions following the strengthening of the balance sheet. A $50 million secured revolving credit facility is expected to be completed in the fourth fiscal quarter to fund future growth.
Unusual Items:
- Acquisitions: Acquired Natural Touch'r' (cosmetic lenses) and Marlow Surgical Technologies. Natural Touch'r' sales contributed over $2.1 million but carry lower margins.
- Debt Redemption: An extraordinary gain is anticipated in the fourth quarter from the redemption of the 10% Senior Subordinated Secured Notes.
- Inventory Write-off: CVI recorded a $300,000 write-off related to an unsuccessful attempt to enter the Canadian over-the-counter pharmaceutical market.
Risks and Contingencies:
- Regulatory/FTC: The FTC requires the Company to develop manufacturing capabilities or find a third-party manufacturer for Natural Touch'r' products within 18 months (extendable by 24 months) or face divestiture.
- Managed Care: Service revenue faces pressure from managed care trends reducing per diems and lengths of stay.
- Accounting Changes: Adoption of SFAS 128 (Earnings Per Share) and SFAS 131 (Segment Reporting) will require restatement of prior periods and new disclosures starting in fiscal 1998/1999.
Investor Verification Checklist
- Debt Redemption Timing: Verify the execution of the $21.9 million note redemption on September 1, 1997, and the associated extraordinary gain.
- FTC Compliance: Monitor progress on establishing manufacturing capabilities for Natural Touch'r' to avoid mandatory divestiture.
- Acquisition Integration: Assess the margin impact of the Natural Touch'r' line and the integration of Marlow Surgical Technologies.
- Credit Facility: Confirm the closing of the proposed $50 million revolving credit facility in the fourth quarter.
- Tax Provision: Review the sustainability of the reduced deferred tax valuation allowance based on future profitability.